MARKET

TROV

TROV

Trovagene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.045
+0.015
+1.48%
Opening 10:27 03/31 EDT
OPEN
1.040
PREV CLOSE
1.030
HIGH
1.180
LOW
1.029
VOLUME
18.37K
TURNOVER
--
52 WEEK HIGH
5.83
52 WEEK LOW
0.7010
MARKET CAP
10.67M
P/E (TTM)
-0.3833
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TROV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TROV stock price target is 14.50 with a high estimate of 23.00 and a low estimate of 6.00.

EPS

TROV News

More
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Trovagene Announces Three New Nominees for Election to Board of Directors
  • PR Newswire · 03/05 13:15
  • TrovaGene EPS beats by $0.14
  • seekingalpha · 02/28 02:39
  • TrovaGene Q4 EPS $(0.51) Up From $(1.09) YoY, Sales $93K Up From $78K YoY
  • Benzinga · 02/27 21:40

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Symbol
Price
%Change

About TROV

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.
More

Webull offers kinds of TrovaGene Inc stock information, including NASDAQ:TROV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TROV stock news, and many more online research tools to help you make informed decisions.